Related Experiment Videos
The cardiotoxicity of anticancer agents
Seminars in Oncology
|March 1, 1982
Summary
Antineoplastic agents, particularly anthracyclines, can cause cardiotoxicity in cancer patients. Early detection methods are needed to manage chemotherapy-induced cardiac disorders, especially in adjuvant therapy settings.
Area of Science:
- Oncology
- Cardiology
Background:
- Antineoplastic therapies are crucial for cancer treatment.
- Cardiotoxicity is a known, albeit variable, side effect of certain chemotherapy drugs.
Purpose of the Study:
- To review the association between antineoplastic agents and cardiotoxicity.
- To highlight the importance of monitoring cardiac health during cancer treatment.
Main Methods:
- Literature review of antineoplastic agents and their cardiac side effects.
- Analysis of cardiotoxicity incidence with different drug classes, focusing on anthracyclines.
Main Results:
- Cardiotoxicity is frequently associated with anthracyclines.
- Most other antineoplastics rarely cause cardiotoxicity.
- Increased use of anthracyclines in early-stage and adjuvant cancer treatment necessitates vigilance.
Conclusions:
- Clinicians must be aware of anthracycline-induced cardiotoxicity, especially in adjuvant settings.
- Improved methods for early detection of chemotherapy-induced cardiotoxicity are essential.
- Cardiac disorders in cancer patients should prompt consideration of chemotherapy-induced cardiac issues.